English

BioStock: Adjutec CEO on preparing for phase I

Report this content

AdjuTec Pharma is pioneering in the realm of antimicrobial resistance with its work rooted in research from the University of Oslo. With its lead product APC148, the biotech firm is edging closer to clinical studies. BioStock talked to CEO Bjørn Klem for an update on the latest developments in the company.

Read the full article at biostock.se:

https://www.biostock.se/2023/11/adjutec-ceo-on-preparing-for-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: Adjutec CEO on preparing for phase I
Tweet this